G 4660
Alternative Names: UIF 100Latest Information Update: 24 Oct 2021
At a glance
- Originator The Solae Company
- Developer National Cancer Institute (USA)
- Class
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 28 Sep 2006 Discontinued - Phase-I for Cancer in USA (unspecified route)
- 07 Nov 2003 Protein Technologies International is now called The Solae Company
- 05 Sep 2001 Phase-I clinical trials for Cancer in USA (Unknown route)